The United States has approved the world’s only twice-yearly HIV prevention shot. This new treatment offers hope to millions by reducing new infections more effectively than current daily pills. The drug, called lenacapavir and made by Gilead Sciences, could change HIV prevention worldwide.
Although a vaccine for HIV is still needed, lenacapavir is seen by experts as the next best option. Studies show it almost stopped new infections in people at high risk. This is better than daily pills that some people forget to take or avoid because of stigma.
Greg Millett, public policy director at an AIDS research foundation, said, “This really has the possibility of ending HIV transmission.”
Current prevention methods include condoms and PrEP, which means taking medicine regularly to stop HIV infection. Some people take daily pills, while others get injections every two months. Lenacapavir’s six-month protection makes it the longest-lasting option. This could help people who do not want to visit the doctor often or who feel judged for taking daily pills.
However, challenges remain. Cuts in U.S. healthcare funding, public health budgets, and foreign aid for HIV prevention may limit how many people can access this new shot. These changes threaten the success of rolling out lenacapavir in the U.S. and abroad.
This shot could be a major step forward in the fight against HIV. It offers a simpler way to protect people at risk, helping to reduce the spread of the virus and improve health outcomes worldwide.
